China Historical Income Statement
| SXTC Stock | USD 0.40 0.02 5.26% |
Historical analysis of China SXT income statement accounts such as Total Revenue of 3.5 M, Gross Profit of 526.3 K, Cost Of Revenue of 1.8 M or Total Operating Expenses of 4.1 M can show how well China SXT Pharmaceuticals performed in making a profits. Evaluating China SXT income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of China SXT's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining China SXT Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether China SXT Pharmaceuticals is a good buy for the upcoming year.
China |
About China Income Statement Analysis
China SXT Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to China SXT shareholders. The income statement also shows China investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
China SXT Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts China SXT Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of China SXT Pharmaceuticals minus its cost of goods sold. It is profit before China SXT operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Cost Of Revenue
Cost of Revenue is found on China SXT Pharmaceuticals income statement and represents the costs associated with goods and services China SXT provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of China SXT Pharmaceuticals. It is also known as China SXT overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from China SXT's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into China SXT Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At present, China SXT's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 3.5 M, whereas Tax Provision is forecasted to decline to 0.00.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.3M | 426.3K | 554.0K | 526.3K | Total Revenue | 2.6M | 2.0M | 1.9M | 3.5M |
China SXT income statement Correlations
Click cells to compare fundamentals
China SXT Account Relationship Matchups
High Positive Relationship
High Negative Relationship
China SXT income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Tax Provision | 440.1K | 252.2K | (101.7K) | (192.7K) | 328.1K | 0.0 | |
| Interest Expense | 3.3M | 1.6M | 218.3K | 476.8K | 544.3K | 758.9K | |
| Selling General Administrative | 2.5M | 3.4M | 5.5M | 5.6M | 2.6M | 2.9M | |
| Total Revenue | 5.2M | 4.8M | 2.6M | 2.0M | 1.9M | 3.5M | |
| Gross Profit | 2.7M | 2.8M | 1.3M | 426.3K | 554.0K | 526.3K | |
| Operating Income | 4.3M | (2.2M) | (5.2M) | (5.6M) | (2.5M) | (2.4M) | |
| Net Income From Continuing Ops | (10.3M) | (2.7M) | (5.7M) | (5.9M) | (3.1M) | (3.3M) | |
| Ebit | 4.3M | (2.2M) | (5.4M) | (5.5M) | (2.6M) | (2.4M) | |
| Cost Of Revenue | 2.5M | 1.9M | 1.4M | 1.5M | 1.4M | 1.8M | |
| Total Operating Expenses | 4.0M | 5.0M | 6.4M | 6.0M | 3.1M | 4.1M | |
| Income Before Tax | (10.4M) | (2.9M) | (5.4M) | (5.9M) | (3.1M) | (3.3M) | |
| Total Other Income Expense Net | (14.7M) | (743.8K) | (218.3K) | (327.3K) | (583.3K) | (612.5K) | |
| Net Income Applicable To Common Shares | 1.5M | (10.3M) | (2.7M) | (5.7M) | (5.2M) | (4.9M) | |
| Net Income | (10.3M) | (2.7M) | (5.7M) | (5.9M) | (3.1M) | (3.3M) | |
| Income Tax Expense | (101.7K) | (192.7K) | 328.1K | 476.8K | 3.0 | 2.85 | |
| Net Interest Income | (3.3M) | (1.6M) | (36.7K) | (476.8K) | (544.3K) | (571.5K) | |
| Depreciation And Amortization | 331.8K | 345.4K | 320.0K | 250.2K | 203.2K | 255.8K | |
| Selling And Marketing Expenses | 1.6M | 1.6M | 924.5K | 387.5K | 433.6K | 717.9K | |
| Other Operating Expenses | 6.5M | 7.0M | 7.8M | 7.6M | 4.4M | 6.5M | |
| Ebitda | 4.6M | (1.9M) | (5.1M) | (5.2M) | (2.4M) | (2.2M) | |
| Reconciled Depreciation | 331.8K | 345.4K | 320.0K | 250.2K | 203.2K | 276.7K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether China SXT Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China SXT's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Sxt Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Sxt Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.426 | Earnings Share (3.57) | Revenue Per Share 2.223 | Quarterly Revenue Growth 0.295 | Return On Assets (0.05) |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.